Literature DB >> 8610976

Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis.

B Metzler1, D C Wraith.   

Abstract

Attempts to induce oral tolerance in a murine model of EAE with either the dominant T-cell epitope or whole protein have failed. These results may, in part, be due to the extraordinarily low affinity for class II MHC displayed by the dominant T-cell epitope. This belief is supported by experiments using a high-affinity analogue of the peptide that was capable of inducing tolerance at a high dose. By contrast, peptide inhalation has proven an effective route for induction of mucosal tolerance in this model. Most importantly, the inhalation of a single peptide could inhibit disease induced by the complex mixture of antigens found in whole myelin. Peptide inhalation was effective both before and after disease induction, and there was a positive correlation between affinity of class II binding and tolerogenicity of a panel of analogues of the N-terminal peptide of myelin basic protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610976     DOI: 10.1111/j.1749-6632.1996.tb21131.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

Review 1.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

Review 2.  Natural and induced regulatory T cells: targets for immunotherapy of autoimmune disease and allergy.

Authors:  Kirsty S Nicolson; David C Wraith
Journal:  Inflamm Allergy Drug Targets       Date:  2006-09

3.  Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor.

Authors:  Ahmed H Badawi; Paul Kiptoo; Wen-Tung Wang; In-Young Choi; Phil Lee; Charlotte M Vines; Teruna J Siahaan
Journal:  Neuropharmacology       Date:  2011-12-17       Impact factor: 5.250

4.  Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the RhD protein in HLA-transgenic mice.

Authors:  Lindsay S Hall; Andrew M Hall; Wendy Pickford; Mark A Vickers; Stanislaw J Urbaniak; Robert N Barker
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

5.  Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

Authors:  D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 6.  Antigen-specific immunotherapy of autoimmune disease: a commentary.

Authors:  D C Wraith
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

7.  Inhibition of T-cell responsiveness by nasal peptide administration: influence of the thymus and differential recovery of T-cell-dependent functions.

Authors:  B Metzler; D C Wraith
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

8.  Intranasal administration of E-selectin to induce immunological tolerization can suppress subarachnoid hemorrhage-induced vasospasm implicating immune and inflammatory mechanisms in its genesis.

Authors:  Toshiyuki Nakayama; Kachikwu Illoh; Christl Ruetzler; Sungyoung Auh; Louis Sokoloff; John Hallenbeck
Journal:  Brain Res       Date:  2006-12-26       Impact factor: 3.252

9.  Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats.

Authors:  X F Bai; H L Li; F D Shi; J Q Liu; B G Xiao; P H Van der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

Review 10.  Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.

Authors:  Prakash Manikwar; Paul Kiptoo; Ahmed H Badawi; Barlas Büyüktimkin; Teruna J Siahaan
Journal:  Med Res Rev       Date:  2011-03-23       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.